drugset

drugset / Trial / NCT01049880

A Research Trial of High Dose Vitamin C and Chemotherapy for Metastatic Pancreatic Cancer

NCT01049880 ↗

Phase 1 Completed 15 enrolled Joseph J. Cullen Holden Comprehensive Cancer Center · collab University of Iowa · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is designed to determine the maximum tolerated dose of vitamin C when given with a standard chemotherapy for people who have metastatic pancreatic cancer.

Timeline

Start: 2009-12
Primary completion: 2013-02
Completion: 2013-03

Publications

Results Welsh JL, Wagner BA, van't Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, Yee NS, Bodeker KL, Du J, Roberts LJ 2nd, Drisko J, Levine M, Buettner GR, Cullen JJ. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013 Mar;71(3):765-75. doi: 10.1007/s00280-013-2070-8. Epub 2013 Feb 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vitamin C	Other / unclassified	15 g	Intravenous
Subject	Vitamin C	Other / unclassified	25 g	Intravenous
Subject	Vitamin C	Other / unclassified	50 g	Intravenous
Subject	Vitamin C	Other / unclassified	75 g	Intravenous
Subject	Vitamin C	Other / unclassified	100 g	Intravenous
Background	Gemcitabine	Small molecule	1000 mg/m2	—

Indications